gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GRDXUtilitiesElectric, Gas & Water Utilities

GridAI Technologies Corp. Common Stock (GRDX)

$4.67−14.00%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$4.67▲ 88.31% in range
Dec 1, 2025Low $2.00 · High $6.80Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

GridAI Technologies closed at $4.67 on Nov 5, down 14.00%, 31.3% below its highest close since Dec 1. Volume of 153.6K shares was 1.38× its 20-day average (above normal).

Split-adjusted performance: +13.3% over one month, +63.9% over six months.

In the quarter ended Jun 30, 2026, revenue was $85.88K, with a net margin of -15023.1%.

Short interest was 99.2K shares at the Oct 15 settlement, down 5.1% from the prior report (1.7% of float, 1.0 days to cover).

Market cap$41.5M8.9M shares
Revenue · quarter$85.9K—
Diluted EPS$-2.01—
P/E · TTM—
Net margin-15,023.1%Gross -42.5%
Dividend yieldNone
Range since Dec 12.00 – 6.80−31.3% from high
Volume153.6K1.38× 20-day avg
Volatility · 60d109.3%Annualised
Short % of float1.7%1.0 days to cover
Net cash-$296.6KCash $1.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −14.3%1M +13.3%3M +70.4%6M +63.9%YTD +0.2%1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Electric, Gas & Water Utilities

Percentile among 119 companies (100 = best)

6-month momentum99
Revenue growth—
Net margin1
Value (low P/E)—
Size10

Industry medians: 6-month return −1.9%, revenue growth +6.9%, net margin 12.2%, P/E 20.9×.

Short interest

Details →
Shares short99.2K−5.1% vs prior
Days to cover1.0Settled Oct 15
% of float1.7%
Short vol. 10d28.9%of daily volume

Closest peers by size in Electric, Gas & Water Utilities

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GRDXGridAI Technologies$4.67−14.00%+63.9%—−15023.1%—$41.5M
OPALOPAL Fuels$1.37−7.43%−41.5%+3.7%−1.8%—$41.5MCompare
HDRNHadron Energy$0.6750−5.33%————$48.3MCompare
SLNGStabilis Solutions$3.73−2.61%−10.3%−31.2%−38.9%—$69.4MCompare
SPRUSpruce Power Holding$1.27−8.63%−63.5%−8.7%10.9%—$24.5MCompare
NFENew Fortress Energy$3.85−5.64%−89.5%+2.8%−118.9%—$22.0MCompare
QRHCQuest Resource Holding$1.04−1.42%−3.7%+7.6%−19.1%—$21.9MCompare
FISNDeep Fission$1.50−32.13%————$88.4MCompare
BESSBimergen Energy$2.64−6.05%——20.6%—$18.7MCompare

News about GridAI Technologies

All news →

No recent articles focused on GridAI Technologies.

Quick answers

What does GridAI Technologies do?
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
What is GRDX's market cap?
$41.51M, based on the Nov 5 close of $4.67.
Does GridAI Technologies pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GRDX is sold short?
99.2K shares, 1.7% of float, as of Oct 15, 2026.
What sector is GRDX in?
Utilities, in the Electric, Gas & Water Utilities industry.

About GridAI Technologies

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

HQ: Boca Raton, FL2 employeesListed Oct 11, 2016enterothera.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology